Yurut-Caloglu, V.Haydaroglu, A.Ozkok, S.Yalman, D.Bolukbasi, Y.2024-06-122024-06-1220091107-06252241-6293https://hdl.handle.net/20.500.14551/21533Purpose. To evaluate the effectiveness of recombinant human erythropoietin (rhEPO) in relation to low hemoglobin (Hb) level, overall tumor response rates, and rhEPO adverse events in patients with lung cancer undergoing radiotherapy (RT). Patients and methods: Thirteen consecutive patients were included. All of them had measurable tumor before RT 150 IU/kg of rhEPO-alpha or -beta were administered 3 times per week, 7-10 clays before RT. The target Hb value was 13 g/dl. Tumor response was assessed 6 weeks after completion of RT Results: Response to rhEPO was seen 62% (n=8) of the patients. Weekly mean Hb increment was 0.69 g/dl (range 0.42-1). The mean Hb value during R T was 13.2 g/dl (range 9-14.7) in responding patients, and 10.7 g/dl (range 9.7-11.8) in non-responding patients (p=0.005). Overall response rates to RT were significantly higher in responding than in non-responding patients (p=0.034). Conclusion: rhEPO increased Hb levels in lung cancer patients undergoing RT. However, safety, and more importantly, indications need further clarifications.eninfo:eu-repo/semantics/closedAccessHemoglobinLung CancerRadiotherapyRhepoCarcinomaCervixArticle143519521Q4WOS:0002704213000252-s2.0-7035007176919810149Q3